IP Library Granted Patent US 11,628,156
Granted Patent B2
US 11,628,156 · App. 16/747,569 · Granted Apr 18, 2023

Terpene-enriched cannabinoid composition and method of treatment

Inventors: Noa Raz (Gizo, IL); Aharon M. Eyal (Jerusalem, IL)
Assignee: BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD
A61K31/352A61K31/015A61K31/045A61K31/05A61K47/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,628,156
App. No.
16/747,569
Granted
Apr 18, 2023
Kind
B2
Abstract

Provided is a therapeutic product comprising at least one cannabinoid; at least one primary terpene; and at least 5% by weight of a non-cannabinoid, non-terpene carrier, wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight/weight ratio in said product is about 0.1 to about 1.0. Also provided is a method of treating certain conditions and/or symptoms in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a product comprising at least one primary terpene. Further provided is a therapeutic product comprising a primary terpene blend, wherein said primary terpene blend comprises five or less terpenes, and wherein each one of those terpenes, where present, independently comprises at least 10% of the total terpene content.

Claims (10)

1. A therapeutic product comprising a monoterpene-enriched extract obtained by extraction with an extractant, said extract comprising:

(i) at least one cannabinoid, wherein at least 80% of said cannabinoid is in a decarboxylated form produced by heating an acid form of said cannabinoid to a temperature of at least 80° C.;

(ii) a primary terpene, wherein said primary terpene is at least one monoterpene and forms at least 30% by weight of the total amount of terpenes in the product, and

(iii) at least 5% by weight of a non-cannabinoid, non-terpene carrier,

wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the total terpenes to total cannabinoids weight/weight ratio in said product is about 0.05 to about 1.0,

forming a monoterpene-enriched cannabinoid product with an enhanced therapeutic effect compared with that of a product comprising the same amount of said at least one cannabinoid and one half the amount of said at least one monoterpene,

wherein the therapeutic product is in a form selected from the group consisting of tablets, gel capsules, sublingual oils, edibles, beverages, cigarettes and vaporizer liquids.

2. The therapeutic product of claim 1 , wherein said at least one monoterpene comprises a mixture of five or less monoterpenes,

wherein each one of said five or less monoterpenes independently comprises at least 10% of the total monoterpene content,

forming a therapeutic product with an enhanced therapeutic effect compared with that of a product comprising one half the amount of the five or less monoterpenes.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2021
From: EYAL, AHARON M.; RAZ, NOA
To: BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD.
Reel/Frame 055231/0868 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2021
From: EYAL, AHARON M.; RAZ, NOA
To: BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD.
Reel/Frame 055174/0349 →
Continuity (5)
Continuation In Part PCTIB2018001062 · Aug 13, 2018
Provisional Application 62639233 · Mar 6, 2018
Provisional Application 62587494 · Nov 17, 2017
Provisional Application 62544847 · Aug 13, 2017
Related Publication 20200261404A1 · Aug 20, 2020